(Q35106942)

6 August 2017

Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance (English)

1 reference

6 August 2017

drug utilization review

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694953

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0168-8510(02)00158-6

24 December 2023

1

Lucie Blais

1 reference

6 August 2017

Julie Couture

2

1 reference

6 August 2017

Elham Rahme

3

1 reference

6 August 2017

Jacques LeLorier

4

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12694953

24 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0168851002001586?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0168-8510(02)00158-6

https://api.elsevier.com/content/article/PII:S0168851002001586?httpAccept=text/plain

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0168-8510(02)00158-6

24 December 2023

1 reference

6 August 2017

64

1 reference

6 August 2017

2

1 reference

6 August 2017

163-172

1 reference

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

Some interim results from a controlled trial of cost sharing in health insurance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

A critical analysis of studies of state drug reimbursement policies: research in need of discipline

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

The effect of a Medicaid drug copayment program on the utilization and cost of prescription services

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

Economic impact of cost-containment strategies in third party programmes in the US (part I).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

Uses of ecologic analysis in epidemiologic research

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900158-6

7 January 2021

The effects of copayments and generic substitution on the use and costs of prescription drugs

2

1 reference

https://api.crossref.org/works/10.1016/S0168-8510(02)00158-6

The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members

24 December 2023

4

1 reference

https://api.crossref.org/works/10.1016/S0168-8510(02)00158-6

The differential impact of copayment on drug use in a Medicaid population

24 December 2023

7

1 reference

https://api.crossref.org/works/10.1016/S0168-8510(02)00158-6

24 December 2023

Identifiers

1 reference

6 August 2017

1 reference